When it comes to heart health, our community is constantly looking for a win.
For years, cardiologists have been holding their breath for a massive new breakthrough in the fight against heart disease — a battle we already know hits Black folks the hardest.
This time, the hype was around a highly anticipated drug tested by Novartis, which everyone hoped would be a powerful new weapon to save our lives.
But in a devastating blow that has left doctors completely shocked, the drug officially failed.
It’s a frustrating and deeply concerning setback for a community that desperately needs real solutions, not more broken promises.
Here’s what went wrong and what it means for your health.
On Friday, Novartis dropped a bombshell in the medical world by announcing that pelacarsen, a drug that many had high hopes for in preventing heart attacks, strokes and cardiovascular-related deaths, didn’t make the cut in its trials.
The news took the cardiology community by surprise because experts were optimistic that this could be a game-changer in heart health. According to recent reporting by The New York Times, the company didn’t provide any further details about the outcome, leaving many scratching their heads.
“Oh no – oh no.” Dr. David Maron, president of the American Society for Preventive Cardiology, couldn’t hide his apprehension when he shared his thoughts about this news in an interview with the publication. “This is a huge blow. I hardly know what to say.”
Similarly, Dr. Harlan Krumholz, a respected cardiologist from Yale, echoed these feelings too. “This is extremely disappointing news,” he said. “We’ve all been looking forward to celebrating.”
In a recent article, reporter Gina Kolata of The Times (she specializes in diseases and treatments), shed light on the disappointment surrounding the unsuccessful study, citing a protein known as lipoprotein (a). This protein has been linked to a major increase in heart disease risk; and until now, most studies — aside from one randomized clinical trial — all suggested that lowering Lp(a) levels could help stave off this serious condition.
Cardiologists were extremely optimistic. A success would play a pivotal role in preventing heart attacks, especially for those individuals who are already proactive about their health by keeping their blood pressure and cholesterol levels in check, avoiding smoking, exercising regularly, and keeping a healthy weight.
The expectations were so high that many doctors considered that these Lp(a) targeting drugs could rival the effectiveness of statins, which are widely used to manage cholesterol levels. This was critical considering how 1 out of every 5 people has high levels of Lp(a) and the most serious levels are found in 10% of the global population.
This means that around 1.4 billion to 2 billion people around the world are affected and high levels can double the risk of having a heart attack or stroke. Even levels that are just a bit above normal can increase the risk by 25%.
Additionally, unlike cholesterol, which can be influenced by what you eat and your weight, Lp(a) levels are not affected by diet or lifestyle changes. It is controlled by your genes and stays the same throughout your life.
The Novartis study was extensive. It spanned seven years, involving 8,323 participants who were grappling with high levels of Lp(a) alongside pre-existing heart issues. They were randomly assigned to receive either the actual medication or a placebo, with both options administered through a convenient pre-filled syringe once a month, much like how many obesity treatments are delivered. This setup made it easier for participants to stick to the regimen.
And here’s the kicker: in a previous study, the Novartis drug lowered Lp(a) levels by 80%, which made it seem obvious that it would help stop heart attacks and strokes, as well.
Dr. Krumholz highlighted another key point: just because numerous studies establish a strong correlation between certain factors and heart disease, it doesn’t necessarily imply cause and effect because what appears to be a direct cause might simply be a marker for another underlying issue, much like how wrinkles serve as a sign of aging rather than a direct cause of health problems.
Cardiologists are no strangers to such surprises, though; they were recently taken aback when a drug aimed at reducing inflammation failed to provide the expected protection against heart disease.
To date, Novartis only made the announcement that their study didn’t succeed. However, according to federal regulations mandating the disclosure of results and how they could sway stock prices, Novartis pledged to present all the findings at the upcoming American Heart Association’s annual meeting in November, where they’ll also share hard documentation in a leading medical journal.
The Novartis study failure is a reminder that we can’t sit around waiting for Big Pharma to hand us a magic pill on a silver platter. When clinical trials miss the mark, it just means the power shifts right back to where it belongs: with us.
Your heart health isn’t a waiting game; it’s an everyday hustle. So, let’s keep control of what we actually can. Book that doctor’s appointment, demand a full blood panel and don’t let anyone dismiss your symptoms.
We protect our own. So let’s start today and take care of our hearts…together.
